Edgewise Therapeutics Inc. Common Stock vs Johnson & Johnson — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while Johnson & Johnson trades at $258 (market cap $599.12B). The key difference: Johnson & Johnson is far larger — about 152.1× Edgewise Therapeutics Inc. Common Stock's market cap, and Johnson & Johnson pays a 2.16% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Johnson & Johnson for 129 Days on average.
| EWTX | JNJ | |
|---|---|---|
Market Cap | $3.94B | $599.12B |
Volume | 810,104 | 16,640,951 |
Sector | Health | Health |
52-Week High | $48.35 | $278.43 |
52-Week Low | $14.89 | $186.00 |
Typical Hold Time | 0 Days | 129 Days |
Enterprise Value | $3.48B | $627.40B |
Dividend Yield | — | 2.16% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JNJ trades at $253.91, down 3.72% on the day, amid a mixed technical and fundamental backdrop. The stock shows strong profitability with a 21.48% net income margin and 25.74% ROE, supported by three consecutive quarterly EPS beats. Analyst consensus is bullish with a $282.73 price target, though recent news highlights competitive pressures and patent cliff concerns. Cash flow trends indicate robust operations but elevated investing outflows.
The outlook remains positive given JNJ's diversified healthcare portfolio and innovation pipeline, but investors face risks from debt levels rising to 24.06% of assets and biosimilar competition. Near-term resistance lies at $265, with support at $257. Institutional sentiment favors growth in pharmaceuticals and medical technology, though macroeconomic and regulatory headwinds persist.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →